Q-omics provides the consensus-scored FAM20C profile across patient tissues and cancer cell-line models. FAM20C expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, FAM20C is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, FAM20C protein abundance shows 16,092 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, THCA, and GBM as cancer lineages where FAM20C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM20C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM20C survival associations across molecular data types. FAM20C RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM20C RNA expression–survival associations across cancer types. High FAM20C expression shows unfavorable associations in LGG, OV, LUAD and CESC, but favorable associations in DLBC and SKCM. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for FAM20C RNA expression.
This table summarizes FAM20C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM20C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM20C shows lower tumor expression in KICH, BLCA and BRCA and higher tumor expression in THCA, LUAD and HNSC. The THCA box plot shows higher FAM20C RNA expression in tumor versus normal tissue (log2 FC = +0.979, t-test p < 0.001).
This table shows molecular features associated with FAM20C in patient tissues and cancer cell lines. In patient samples, FAM20C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM20C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and CNS.
